• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

聚乳酸-羟基乙酸共聚物微/纳米颗粒递送系统作为耐药性新治疗方法的最新进展

Recent advances in PLGA micro/nanoparticle delivery systems as novel therapeutic approach for drug-resistant .

作者信息

Shao Liqun, Shen Shu, Liu Huan

机构信息

Department of Respiratory, Shenyang Tenth People's Hospital, Shenyang Chest Hospital, Shenyang, China.

出版信息

Front Bioeng Biotechnol. 2022 Jul 22;10:941077. doi: 10.3389/fbioe.2022.941077. eCollection 2022.

DOI:10.3389/fbioe.2022.941077
PMID:35935487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9355142/
Abstract

is a severe infectious disease caused by and is a significant public health concern globally. The World Health Organization (WHO) recommends a combination regimen of several drugs, such as rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol (ETB), to treat t. However, these drugs have low plasma concentrations after oral administration and require multiple high doses, which may lead to the occurrence and development of drug-resistant . Micro/Nanotechnology drug delivery systems have considerable potential in treating drug-resistant , allowing the sustained release of the drug and delivery of the drug to a specific target. These system properties could improve drug bioavailability, reduce the dose and frequency of administration, and solve the problem of non-adherence to the prescribed therapy. This study systematically reviewed the recent advances in PLGA micro/nanoparticle delivery systems as a novel therapeutic approach for drug-resistant .

摘要

是由……引起的一种严重传染病，是全球重大的公共卫生问题。世界卫生组织（WHO）推荐使用几种药物的联合治疗方案，如利福平（RIF）、异烟肼（INH）、吡嗪酰胺（PZA）和乙胺丁醇（ETB）来治疗……。然而，这些药物口服后血浆浓度较低，需要多次高剂量给药，这可能导致耐药性……的发生和发展。微/纳米技术药物递送系统在治疗耐药性……方面具有巨大潜力，可实现药物的持续释放并将药物递送至特定靶点。这些系统特性可以提高药物生物利用度，减少给药剂量和频率，并解决不遵守规定治疗方案的问题。本研究系统综述了PLGA微/纳米颗粒递送系统作为耐药性……的一种新型治疗方法的最新进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/8c276b5e2003/fbioe-10-941077-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/ce07c397c09c/fbioe-10-941077-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/945517023e9a/fbioe-10-941077-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/50f8f5ba0bfb/fbioe-10-941077-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/38216b7a7b71/fbioe-10-941077-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/1e12e38f35e9/fbioe-10-941077-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/3fddf378134d/fbioe-10-941077-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/50b2ce983f03/fbioe-10-941077-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/ab2b90ddc056/fbioe-10-941077-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/d98ad9bfbc4e/fbioe-10-941077-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/5bbb76627798/fbioe-10-941077-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/e1048ce28bfe/fbioe-10-941077-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/8c276b5e2003/fbioe-10-941077-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/ce07c397c09c/fbioe-10-941077-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/945517023e9a/fbioe-10-941077-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/50f8f5ba0bfb/fbioe-10-941077-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/38216b7a7b71/fbioe-10-941077-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/1e12e38f35e9/fbioe-10-941077-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/3fddf378134d/fbioe-10-941077-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/50b2ce983f03/fbioe-10-941077-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/ab2b90ddc056/fbioe-10-941077-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/d98ad9bfbc4e/fbioe-10-941077-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/5bbb76627798/fbioe-10-941077-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/e1048ce28bfe/fbioe-10-941077-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0c2/9355142/8c276b5e2003/fbioe-10-941077-g012.jpg

相似文献

1
Recent advances in PLGA micro/nanoparticle delivery systems as novel therapeutic approach for drug-resistant .聚乳酸-羟基乙酸共聚物微/纳米颗粒递送系统作为耐药性新治疗方法的最新进展
Front Bioeng Biotechnol. 2022 Jul 22;10:941077. doi: 10.3389/fbioe.2022.941077. eCollection 2022.
2
Nanotechnology-Based Drug Delivery Systems for Treatment of Tuberculosis--A Review.基于纳米技术的结核病治疗药物递送系统——综述
J Biomed Nanotechnol. 2016 Feb;12(2):241-60. doi: 10.1166/jbn.2016.2149.
3
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.《2006年抗结核药物国际共识指南：肺结核、肺外结核及特殊情况结核病的管理》
J Assoc Physicians India. 2006 Mar;54:219-34.
4
[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].含吡嗪酰胺的6个月方案治疗初治肺结核患者的疗效及问题
Kekkaku. 2001 Jan;76(1):33-43.
5
[Prevalence and transmission of pyrazinamide-resistant in Hunan Province,China].[中国湖南省吡嗪酰胺耐药的流行情况与传播]
Zhonghua Jie He He Hu Xi Za Zhi. 2022 Jul 12;45(7):677-685. doi: 10.3760/cma.j.cn112147-20211219-00904.
6
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发：现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
7
Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.巴基斯坦开伯尔-普赫图赫瓦省吡嗪酰胺耐药情况
Microb Drug Resist. 2018 Nov;24(9):1417-1421. doi: 10.1089/mdr.2017.0234. Epub 2018 Mar 27.
8
Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.异烟肼对利福平-吡嗪酰胺联合用药在小鼠结核病模型中活性的矛盾效应。
Antimicrob Agents Chemother. 2009 Oct;53(10):4178-84. doi: 10.1128/AAC.00830-09. Epub 2009 Jul 20.
9
Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.坦桑尼亚农村地区儿童结核病一线药物的药代动力学。
J Pediatric Infect Dis Soc. 2020 Feb 28;9(1):14-20. doi: 10.1093/jpids/piy106.
10
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.用于实验性结核病的基于聚（DL-丙交酯-共-乙交酯）纳米颗粒的可吸入持续给药系统
J Antimicrob Chemother. 2003 Dec;52(6):981-6. doi: 10.1093/jac/dkg477. Epub 2003 Nov 12.

引用本文的文献

1
Insights into Natural Products from Marine-Derived Fungi with Antimycobacterial Properties: Opportunities and Challenges.对具有抗分枝杆菌特性的海洋来源真菌天然产物的见解：机遇与挑战。
Mar Drugs. 2025 Jul 3;23(7):279. doi: 10.3390/md23070279.
2
Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases.纳米技术推动的针对传染病的鼻内疫苗递送系统的进展。
Front Immunol. 2025 May 9;16:1573037. doi: 10.3389/fimmu.2025.1573037. eCollection 2025.
3
Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment.

本文引用的文献

1
Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.评估氯法齐明单独使用和与一线药物联合使用对体外结核分枝杆菌的疗效。
J Glob Antimicrob Resist. 2022 Jun;29:343-352. doi: 10.1016/j.jgar.2022.03.008. Epub 2022 Mar 23.
2
Levofloxacin-Loaded Nanosonosensitizer as a Highly Efficient Therapy for Bacillus Calmette-Guérin Infections Based on Bacteria-Specific Labeling and Sonotheranostic Strategy.载左氧氟沙星的纳米声敏剂基于细菌特异性标记和声治疗策略的高效治疗卡介苗感染。
Int J Nanomedicine. 2021 Sep 24;16:6553-6573. doi: 10.2147/IJN.S321631. eCollection 2021.
3
对抗耐多药结核病的创新策略：药物递送系统与治疗的进展
Microorganisms. 2025 Mar 24;13(4):722. doi: 10.3390/microorganisms13040722.
4
Mannosamine-Engineered Nanoparticles for Precision Rifapentine Delivery to Macrophages: Advancing Targeted Therapy Against Mycobacterium Tuberculosis.用于将利福喷汀精准递送至巨噬细胞的甘露糖胺工程化纳米颗粒：推进抗结核分枝杆菌的靶向治疗
Drug Des Devel Ther. 2025 Mar 19;19:2081-2102. doi: 10.2147/DDDT.S505682. eCollection 2025.
5
Pluronic F127/lecithin PLGA nanoparticles as carriers of monocyte-targeted jakinibs: a potential therapeutic platform.普朗尼克F127/卵磷脂聚乳酸-羟基乙酸共聚物纳米颗粒作为单核细胞靶向性贾金尼布的载体：一个潜在的治疗平台。
Nanomedicine (Lond). 2025 Jan;20(1):9-22. doi: 10.1080/17435889.2024.2415877. Epub 2024 Oct 29.
6
Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines.颠覆辅助药物研发模式：利用人工智能开发新一代癌症疫苗。
Front Immunol. 2024 Aug 14;15:1438030. doi: 10.3389/fimmu.2024.1438030. eCollection 2024.
7
Sorafenib and Piperine co-loaded PLGA nanoparticles: Development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line.索拉非尼和胡椒碱共载聚乳酸-羟基乙酸共聚物纳米粒：制备、表征及其对肝癌细胞系的抗癌活性
Saudi Pharm J. 2024 May;32(5):102064. doi: 10.1016/j.jsps.2024.102064. Epub 2024 Apr 7.
8
Recent Advances in Nanotechnology-Based Strategies for Bone Tuberculosis Management.基于纳米技术的骨结核治疗策略的最新进展
Pharmaceuticals (Basel). 2024 Jan 29;17(2):170. doi: 10.3390/ph17020170.
9
Development of High-Loading Trastuzumab PLGA Nanoparticles: A Powerful Tool Against HER2 Positive Breast Cancer Cells.高载量曲妥珠单抗 PLGA 纳米粒的研制：一种针对 HER2 阳性乳腺癌细胞的有力工具。
Int J Nanomedicine. 2023 Nov 24;18:6999-7020. doi: 10.2147/IJN.S429898. eCollection 2023.
10
Importance of adjuvant selection in tuberculosis vaccine development: Exploring basic mechanisms and clinical implications.辅助剂选择在结核病疫苗研发中的重要性：探索基本机制与临床意义
Vaccine X. 2023 Oct 29;15:100400. doi: 10.1016/j.jvacx.2023.100400. eCollection 2023 Dec.
PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy.
携带 TLR3/RIG-I 配体 Riboxxim 的 PLGA 微粒疫苗与免疫检查点阻断联合用于有效的癌症免疫治疗。
Nat Commun. 2021 May 18;12(1):2935. doi: 10.1038/s41467-021-23244-3.
4
Clofazimine functionalized polymeric nanoparticles for brain delivery in the tuberculosis treatment.克拉霉素功能化聚合物纳米粒用于结核病治疗的脑内递药。
Int J Pharm. 2021 Jun 1;602:120655. doi: 10.1016/j.ijpharm.2021.120655. Epub 2021 Apr 27.
5
Mannose receptor targeted bioadhesive chitosan nanoparticles of clofazimine for effective therapy of tuberculosis.用于有效治疗结核病的靶向甘露糖受体的氯法齐明生物粘附性壳聚糖纳米颗粒。
Saudi Pharm J. 2020 Dec;28(12):1616-1625. doi: 10.1016/j.jsps.2020.10.008. Epub 2020 Oct 24.
6
Local drug delivery systems for inflammatory diseases: Status quo, challenges, and opportunities.局部给药系统治疗炎症性疾病：现状、挑战与机遇。
J Control Release. 2021 Feb 10;330:438-460. doi: 10.1016/j.jconrel.2020.12.025. Epub 2020 Dec 31.
7
Drug resistant Tuberculosis: A review.耐药结核病：综述。
Comp Immunol Microbiol Infect Dis. 2021 Feb;74:101574. doi: 10.1016/j.cimid.2020.101574. Epub 2020 Nov 16.
8
Clinically established biodegradable long acting injectables: An industry perspective.临床认可的可生物降解长效注射剂：行业视角
Adv Drug Deliv Rev. 2020 Dec;167:19-46. doi: 10.1016/j.addr.2020.11.008. Epub 2020 Nov 14.
9
Development of Rifapentine-Loaded PLGA-Based Nanoparticles: In vitro Characterisation and in vivo Study in Mice.利福喷丁载药 PLGA 纳米粒的研制：体外特性研究和体内实验研究。
Int J Nanomedicine. 2020 Oct 6;15:7491-7507. doi: 10.2147/IJN.S257758. eCollection 2020.
10
Recent advances in the formulation of PLGA microparticles for controlled drug delivery.用于控释给药的聚乳酸-羟基乙酸共聚物（PLGA）微粒制剂的最新进展。
Prog Biomater. 2020 Dec;9(4):153-174. doi: 10.1007/s40204-020-00139-y. Epub 2020 Oct 15.